Brooks Announces GENEWIZ Selected as Genome Characterization Center by the National Cancer Institute

published 12.01.2021 22:05


Brooks Life Sciences' GENEWIZ division is a leading provider of gene sequencing and gene synthesis services.

"The data NCI generates for the entire cancer research community across the nation supports the mission to advance scientific knowledge and help all people live longer, healthier lives," shared Dr. Ginger Zhou, vice president of genomics services at GENEWIZ.

"This contract for Brooks to provide whole exome sequencing to the National Cancer Institute demonstrates the outstanding reputation of GENEWIZ in the cancer research community," commented Steve Schwartz, president and CEO of Brooks Automation.

The NCI, the nation's leader in cancer research and part of the National Institutes of Health (NIH), chose GENEWIZ to provide whole exome sequencing to new research projects at its Center for Cancer Genomics for a period of three years.

Similar Posts